Six-Year Perspectives on the Safety and Tolerability of Nefazodone

Clicks: 74
ID: 267025
2002
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #236 of 273 articles by views in the journal of clinical psychiatry

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 273 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Article AbstractBecause this piece does not have an abstract, we have provided for your benefit the first 3 sentences of the full text.33 Comparative Safety and Tolerability of Nefazodone. David L. Dunner, M.D., and Lyle K. Laird, Pharm.D., B.C.P.P. From the Department of Psychiatry and Behavioral Sciences, University of Washington, and the Center for Anxiety and Depression, Seattle (Dr. Dunner); and the Neuroscience Medical Affairs Department, Bristol-Myers Squibb Company, and the School of Pharmacy, University of Colorado Health Sciences Center, Denver (Dr. Laird). Reprint requests to: David L. Dunner, M.D., Department of Psychiatry and Behavioral Sciences, University of Washington, Center for Anxiety and Depression, 4225 Roosevelt Way, N.E., Suite 306C, Seattle, WA 98105-6099 (e-mail: ddunner@u.washington.edu). 36 Nefazodone: Discontinuation Issues and Safety in Chronic Major Depression. John Zajecka, M.D., and LaGenia Bailey, Pharm.D. From the Department of Psychiatry, Rush-Presbyterian-St. Luke's Medical Center (Dr. Zajecka), and the Neuroscience Medical Affairs Department, Bristol-Myers Squibb Company (Dr. Bailey), Chicago, Ill. Reprint requests to: John Zajecka, M.D., Department of Psychiatry, Rush-Presbyterian-St. Luke's Medical Center, 1725 West Harrison St., Ste. 955, Chicago, IL 60612 (e-mail: jzajecka@rush.edu). 38 Effects of Nefazodone on Body Weight. Norman Sussman, M.D., and Julia L. Seabolt, Pharm.D. From the Department of Psychiatry, New York University School of Medicine (Dr. Sussman), and the Neuroscience Medical Affairs Department, Bristol-Myers Squibb Company (Dr. Seabolt), New York. Reprint requests to: Norman Sussman, M.D., Department of Psychiatry, New York University School of Medicine, 150 E. 58th St., 27th Floor, New York, NY 10155 (e-mail: Sussman01@aol.com).
Reference Key
safety2002thesix-year Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Comparative Safety;Tolerability of Nefazodone. David L. Dunner;Lyle K. Laird;
Journal the journal of clinical psychiatry
Year 2002
DOI
DOI not found
URL
https://www.psychiatrist.com/jcp/depression/six-perspectives-safety-tolerability-nefazodone/
Keywords

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.